Chronic Pain Clinical Trials in the UK (2026): Non-Opioid Treatments, Neuromodulation and Digital Therapies
Chronic pain affects over 28 million people in the UK and is the leading cause of disability. With the opioid crisis forcing a reassessment of pain management, clinical trials are exploring innovative non-opioid approaches — from targeted nerve drugs to neuromodulation devices and digital health interventions.
The Non-Opioid Future of Pain Management
The search for effective, non-addictive pain treatments has become one of the most important areas of clinical research. UK trials are testing Nav1.7 inhibitors — drugs that block a specific sodium channel essential for pain signalling without affecting other nerve functions. Nerve growth factor (NGF) inhibitors target a different pain pathway and have shown promise for osteoarthritis and chronic lower back pain. Cannabinoid-based medicines are being rigorously tested for the first time in proper randomised controlled trials.
Neuromodulation and Device-Based Approaches
Neuromodulation — using electrical or magnetic stimulation to modulate pain signals — is an expanding area of UK trials. Spinal cord stimulation for chronic back and leg pain, vagus nerve stimulation for migraine and cluster headache, and peripheral nerve stimulation for specific pain conditions are all being studied. These approaches are particularly relevant for patients who have not responded to conventional treatments and wish to avoid or reduce opioid use.
Digital Pain Management Programmes
Digital health trials are testing app-based pain management programmes that combine cognitive behavioural therapy, mindfulness, graded exercise therapy, and pain education. These programmes aim to provide evidence-based pain management to patients who cannot easily attend face-to-face appointments. UK trials have shown promising results for digital approaches in managing chronic lower back pain, fibromyalgia, and osteoarthritis.
Osteoporosis and Bone Health Trials
Osteoporosis trials in the UK are testing next-generation bone-building (anabolic) therapies that actually create new bone rather than just slowing loss. Sclerostin inhibitors, which unlock the body's natural bone-building mechanisms, are a particularly exciting area. Trials are also testing improved formulations of existing drugs with fewer side effects and longer dosing intervals, making treatment more convenient for patients.